BioCryst Announces Closure of Internal Discovery Programs by End of 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
BioCryst announced that it will discontinue its internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026. Following a strategic review and scientific diligence of its research capabilities, programs and priorities, BioCryst said that prioritizing external innovation will be the most nimble and capital efficient path to building a sustainable rare disease pipeline beyond its current clinical stage programs. As a part of this strategic shift, the company will discontinue its internal discovery programs and focus on identifying and advancing opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCRX
Wall Street analysts forecast BCRX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 9.550
Low
8.00
Averages
19.45
High
32.00
Current: 9.550
Low
8.00
Averages
19.45
High
32.00
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioCryst Accelerates Rare Disease Pipeline Growth Through Strategic Shift
- Strategic Shift: BioCryst announced the discontinuation of its internal discovery programs and the closure of its Birmingham, Alabama, Discovery Center of Excellence, prioritizing external innovation to build a sustainable rare disease pipeline in a more nimble and capital-efficient manner.
- Clinical Trial Progress: Enrollment for the Phase 3 ALPHA-ORBIT study of navenibart has been completed, positioning it to potentially be the first hereditary angioedema therapy with both 3- and 6-month dosing, with efficacy data expected in Q3 2027.
- Improved Financial Outlook: BioCryst has revised its 2026 non-GAAP operating expense guidance down from $450-$470 million to $420-$440 million, demonstrating the company's ability to control costs during its transition.
- Product Launch Plans: The previously disclosed manufacturing delay of ORLADEYO oral pellets has been resolved, with the product expected to be available in early August 2026, further enhancing the company's competitive position in the rare disease market.
See More
BioCryst Pharmaceuticals Shares Surge Amid Positive Therapy Data
- Strong Stock Performance: BioCryst Pharmaceuticals (BCRX) shares have surged for six consecutive trading days, gaining over 33% and reaching a 52-week high on Thursday, reflecting strong investor confidence in its future performance.
- Market Sentiment Extremely Bullish: Data from Stocktwits indicates that retail sentiment for BCRX remains in the 'extremely bullish' zone, with message volumes surging 360% within a 24-hour period, suggesting investor anticipation for a breakout above key resistance levels.
- Promising Orladeyo Therapy: Recent data from BioCryst shows that its Orladeyo therapy significantly reduced hereditary angioedema attacks in children aged 2 to 12, with medical care needs dropping from 22 to just 3, and projected revenue for Orladeyo in 2026 is expected to reach $625 million to $645 million, accounting for 97.7% to 98.4% of total revenue.
- Advancement in Drug Development: BioCryst is also advancing a potential treatment for Netherton syndrome, with Phase 1 data expected by year-end, further enhancing the company's competitive position in the rare disease market.
See More
Bitdeer and BioCryst Options Trading Activity Surges
- Surge in Bitdeer Options: Bitdeer Technologies Group (BTDR) has seen an options trading volume of 60,785 contracts today, equating to approximately 6.1 million shares, which represents about 49.9% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Call Option Activity: Within BTDR, the $20 strike call option has been particularly active, with 30,291 contracts traded today, representing around 3.0 million shares, reflecting a strong bullish sentiment among investors regarding the stock's potential upside.
- BioCryst Options Trading: BioCryst Pharmaceuticals Inc (BCRX) has recorded an options trading volume of 21,183 contracts today, translating to approximately 2.1 million shares, which is about 49.1% of its average daily trading volume over the past month, showcasing market interest in its growth prospects.
- Active BCRX Call Options: For BCRX, the $15 strike call option has also seen significant activity, with 8,347 contracts traded today, representing approximately 834,700 shares, indicating investor optimism about the company's future performance.
See More
BioCryst Releases New Data on ORLADEYO and Navenibart
- ORLADEYO Efficacy: In the APeX-P study, patients treated with ORLADEYO experienced only 0.169 hereditary angioedema (HAE) attacks per month, a significant reduction from 0.691 attacks on standard-of-care therapies, highlighting the drug's effectiveness in lowering attack frequency.
- Standard Treatment Comparison: Over a 12-week observation period, patients on standard treatment averaged 22 HAE attacks, which dropped to just 3 attacks with ORLADEYO, indicating its potential to significantly improve patients' quality of life through long-term prevention of HAE attacks.
- Navenibart Development Progress: BioCryst is developing Navenibart as a long-acting treatment, with preliminary data showing effective reduction of moderate to severe HAE attacks across various body mass index (BMI) and age groups, supporting its application in future clinical trials.
- Clinical Trial Support: The Phase 1b/2 ALPHA-STAR trial results for Navenibart indicate reduced on-demand medication use among treated patients, with good drug tolerability, laying the groundwork for its upcoming Phase 3 ALPHA-ORBIT trial, which could offer new treatment options for HAE patients.
See More
BioCryst Reaffirms ORLADEYO Revenue Guidance Amid Navenibart Trial Progress
- Revenue Guidance Reaffirmed: BioCryst reaffirms its 2023 ORLADEYO revenue guidance of $625 million to $645 million, with Q1 revenue at $148.3 million aligning with expectations, indicating strong patient demand and reimbursement trends that are expected to drive U.S. sales towards the $1 billion target.
- Pediatric Launch Delayed: The pediatric launch of ORLADEYO was delayed due to a batch-specific manufacturing issue, which is deemed isolated and non-safety-related; early prescriptions have exceeded expectations, indicating strong market demand, and once available, this could positively impact sales.
- Navenibart Trial Progress: BioCryst's navenibart Phase 3 trial is nearing completion of enrollment, with top-line data expected in Q3 next year and a BLA filing planned by the end of 2027, showcasing the company's ongoing R&D advancements in rare diseases.
- Strong Financial Position: BioCryst reported a cash position of $330 million at the end of Q1, with expectations of profitability this year and increased profitability next year, reflecting robust development in both commercialization and R&D efforts.
See More
BioCryst Pharmaceuticals Q1 2026 Earnings Call Highlights
- Strong Financial Performance: BioCryst reported ORLADEYO net revenue of $148.3 million for Q1 2026, aligning with expectations and reflecting a 21% year-over-year increase, indicating robust market demand and sustained revenue growth potential.
- R&D Progress on Track: The pivotal ALPHA-ORBIT trial for navenibart has exceeded expectations, with approximately 145 patients expected to be enrolled by the end of next month, laying the groundwork for future regulatory submissions and enhancing the company's competitive position in the rare disease space.
- Market Competition Management: Despite facing new competition, demand for new prescriptions among patients aged 12 and older remains stable, demonstrating continued trust in ORLADEYO from both physicians and patients, which is expected to drive further market share growth.
- Supply Chain Challenges: Although a manufacturing issue for pediatric formulations has been identified that will delay initial product fulfillment, management has stated that this delay will not impact the revenue guidance for 2026, reflecting the company's confidence in future performance.
See More
BioCryst Accelerates Rare Disease Pipeline Growth Through Strategic Shift
- Strategic Shift: BioCryst announced the discontinuation of its internal discovery programs and the closure of its Birmingham, Alabama, Discovery Center of Excellence, prioritizing external innovation to build a sustainable rare disease pipeline in a more nimble and capital-efficient manner.
- Clinical Trial Progress: Enrollment for the Phase 3 ALPHA-ORBIT study of navenibart has been completed, positioning it to potentially be the first hereditary angioedema therapy with both 3- and 6-month dosing, with efficacy data expected in Q3 2027.
- Improved Financial Outlook: BioCryst has revised its 2026 non-GAAP operating expense guidance down from $450-$470 million to $420-$440 million, demonstrating the company's ability to control costs during its transition.
- Product Launch Plans: The previously disclosed manufacturing delay of ORLADEYO oral pellets has been resolved, with the product expected to be available in early August 2026, further enhancing the company's competitive position in the rare disease market.
See More
BioCryst Pharmaceuticals Shares Surge Amid Positive Therapy Data
- Strong Stock Performance: BioCryst Pharmaceuticals (BCRX) shares have surged for six consecutive trading days, gaining over 33% and reaching a 52-week high on Thursday, reflecting strong investor confidence in its future performance.
- Market Sentiment Extremely Bullish: Data from Stocktwits indicates that retail sentiment for BCRX remains in the 'extremely bullish' zone, with message volumes surging 360% within a 24-hour period, suggesting investor anticipation for a breakout above key resistance levels.
- Promising Orladeyo Therapy: Recent data from BioCryst shows that its Orladeyo therapy significantly reduced hereditary angioedema attacks in children aged 2 to 12, with medical care needs dropping from 22 to just 3, and projected revenue for Orladeyo in 2026 is expected to reach $625 million to $645 million, accounting for 97.7% to 98.4% of total revenue.
- Advancement in Drug Development: BioCryst is also advancing a potential treatment for Netherton syndrome, with Phase 1 data expected by year-end, further enhancing the company's competitive position in the rare disease market.
See More
Bitdeer and BioCryst Options Trading Activity Surges
- Surge in Bitdeer Options: Bitdeer Technologies Group (BTDR) has seen an options trading volume of 60,785 contracts today, equating to approximately 6.1 million shares, which represents about 49.9% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Call Option Activity: Within BTDR, the $20 strike call option has been particularly active, with 30,291 contracts traded today, representing around 3.0 million shares, reflecting a strong bullish sentiment among investors regarding the stock's potential upside.
- BioCryst Options Trading: BioCryst Pharmaceuticals Inc (BCRX) has recorded an options trading volume of 21,183 contracts today, translating to approximately 2.1 million shares, which is about 49.1% of its average daily trading volume over the past month, showcasing market interest in its growth prospects.
- Active BCRX Call Options: For BCRX, the $15 strike call option has also seen significant activity, with 8,347 contracts traded today, representing approximately 834,700 shares, indicating investor optimism about the company's future performance.
See More
BioCryst Releases New Data on ORLADEYO and Navenibart
- ORLADEYO Efficacy: In the APeX-P study, patients treated with ORLADEYO experienced only 0.169 hereditary angioedema (HAE) attacks per month, a significant reduction from 0.691 attacks on standard-of-care therapies, highlighting the drug's effectiveness in lowering attack frequency.
- Standard Treatment Comparison: Over a 12-week observation period, patients on standard treatment averaged 22 HAE attacks, which dropped to just 3 attacks with ORLADEYO, indicating its potential to significantly improve patients' quality of life through long-term prevention of HAE attacks.
- Navenibart Development Progress: BioCryst is developing Navenibart as a long-acting treatment, with preliminary data showing effective reduction of moderate to severe HAE attacks across various body mass index (BMI) and age groups, supporting its application in future clinical trials.
- Clinical Trial Support: The Phase 1b/2 ALPHA-STAR trial results for Navenibart indicate reduced on-demand medication use among treated patients, with good drug tolerability, laying the groundwork for its upcoming Phase 3 ALPHA-ORBIT trial, which could offer new treatment options for HAE patients.
See More
BioCryst Reaffirms ORLADEYO Revenue Guidance Amid Navenibart Trial Progress
- Revenue Guidance Reaffirmed: BioCryst reaffirms its 2023 ORLADEYO revenue guidance of $625 million to $645 million, with Q1 revenue at $148.3 million aligning with expectations, indicating strong patient demand and reimbursement trends that are expected to drive U.S. sales towards the $1 billion target.
- Pediatric Launch Delayed: The pediatric launch of ORLADEYO was delayed due to a batch-specific manufacturing issue, which is deemed isolated and non-safety-related; early prescriptions have exceeded expectations, indicating strong market demand, and once available, this could positively impact sales.
- Navenibart Trial Progress: BioCryst's navenibart Phase 3 trial is nearing completion of enrollment, with top-line data expected in Q3 next year and a BLA filing planned by the end of 2027, showcasing the company's ongoing R&D advancements in rare diseases.
- Strong Financial Position: BioCryst reported a cash position of $330 million at the end of Q1, with expectations of profitability this year and increased profitability next year, reflecting robust development in both commercialization and R&D efforts.
See More
BioCryst Pharmaceuticals Q1 2026 Earnings Call Highlights
- Strong Financial Performance: BioCryst reported ORLADEYO net revenue of $148.3 million for Q1 2026, aligning with expectations and reflecting a 21% year-over-year increase, indicating robust market demand and sustained revenue growth potential.
- R&D Progress on Track: The pivotal ALPHA-ORBIT trial for navenibart has exceeded expectations, with approximately 145 patients expected to be enrolled by the end of next month, laying the groundwork for future regulatory submissions and enhancing the company's competitive position in the rare disease space.
- Market Competition Management: Despite facing new competition, demand for new prescriptions among patients aged 12 and older remains stable, demonstrating continued trust in ORLADEYO from both physicians and patients, which is expected to drive further market share growth.
- Supply Chain Challenges: Although a manufacturing issue for pediatric formulations has been identified that will delay initial product fulfillment, management has stated that this delay will not impact the revenue guidance for 2026, reflecting the company's confidence in future performance.
See More
